CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 54 enrolled
Drug / intervention
RBT-1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03893799
NCT03893799Phase 1Completed
CompareCT.gov

A Phase 1b Dose-escalating Study With RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease

Renibus Therapeutics, Inc.·interventional·Posted Mar 28, 2019·Updated Aug 7, 2025

In Brief

A Phase 1 clinical trial evaluating RBT-1 for Healthy Volunteers and Chronic Kidney Disease. Completed, enrolled 54 participants across 1 site.

Detailed Summary

This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with Stage 3/4 CKD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Chronic Kidney Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedMar 28, 2019
Enrollment StartAug 27, 2019
Primary CompletionApr 22, 2020
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.3 years ago

Interventions

RBT-1drug

Single intravenous administration